Physician profile
Eric B Thomson
NPI 1386750065
$400.81
in general payments reported to CMS, 2019-2025
13 companies · $75.31 in 2025
The $75.31 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $42.39 · 2021: $109 · 2022: $31.50 · 2023: $15.15 · 2025: $75.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $90.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $90.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $99.99 | 2019 | |
| Eisai INC. | $55.15 | 2020-2021 | |
| Amgen INC. | $50.40 | 2022-2025 | Evenity, Prolia, Prolia |
| Astrazeneca Pharmaceuticals Lp | $29.90 | 2025 | Breztri, Airsupra |
| Mauna Kea Technologies, INC. | $27.48 | 2019 | |
| Lilly USA, LLC | $26.14 | 2021 | |
| Abbott Laboratories | $24.05 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $18.31 | 2021 | |
| Currax Pharmaceuticals LLC | $18.00 | 2021 | |
| Abbvie INC. | $17.61 | 2022 | |
| Amarin Pharma, INC. | $11.31 | 2020 | |
| Merck Sharp & Dohme LLC | $11.26 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Thomson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.